Biotech Values

[DewDiligence]

> DNDN – Has all follow-up from 9901 and 9902A been completed? If not, isn't it possible that they may gather additional supportive survival data by waiting until the mfg part of the BLA is ready?<

Patient follow-up ended at three years, so the above is not a reason to wait.